Abatacept in Immune Checkpoint Inhibitor Myocarditis
Status: Recruiting
Conditions: Myocarditis
Location:
"Beth Israel Deaconess Medical Center "Allegheny-Singer Research Institution
Boston Medical Center
Brigham and Women's Hospital
Cedars-Sinai Medical Center
Lehigh Valley Health Network
Memorial Sloan Kettering Cancer Center
University of California Los Angeles
University of Kansas Medical Center
University of Kentucky
University of Michigan
University of North Carolina Chapel Hill
University of Texas Southwestern
University of Utah
City/State:
Los Angeles, California
Los Angeles, California
Kansas City, Kansas
Lexington, Kentucky
Boston, Massachusetts
Ann Arbor, Michigan
New York, New York
Chapel Hill, North Carolina
Bethlehem, Pennsylvania
Pittsburgh, Pennsylvania
Dallas, Texas
Houston, Texas
Salt Lake City, Utah
Contact Information:
Kiranbir Josan, MD
Eric Yang, MD
Charles Porter, MD
Amit Arbune, MD
Daniel Zlotoff, MD, PhD 617-726-2000 [email protected]
Aarti Asnani or Abul Aritizia, MD
Omar Siddiqi
Anju Nohria, MD [email protected]
Salim Hayek, MD [email protected]
Dipti Gupta, MD
Brian Jensen, MD
Nicholas Trask
Valentyna Ivanova
Saketh Nadimpalli [email protected]
Nicolas Palaskas [email protected]
Anees Daud, MD
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.